natgillin/translations-raw huggingface dataset:
The morning dose should be taken at least 30 minutes before the morning meal, whereas the evening dose can be taken with or without food.
Jutranji odmerek je treba vzeti najmanj 30 minut pred jutranjim obrokom, medtem ko se večerni odmerek lahko vzame skupaj s hrano ali brez nje.
The most abundant circulating dexmedetomidine metabolites are two isomeric N- glucuronides.
Presnovka deksmedetomidina, ki sta v krvi navzoča v največjih količinah, sta dva izomerna N-glukuronida.
The most abundant metabolite is 8-hydroxy-ibafloxacin, which is also microbiologically active.
Presnovek, ki nastaja v največji količini, je 8-hidroksi-ibafloksacin, ki je tudi mikrobiološko aktiven.
The most abundant metabolites of tasimelteon have less than one- tenth of the binding affinity of the parent molecule for both the MT1 and MT2 receptors.
Količinsko najpomembnejši presnovki tasimelteona imajo manj kot eno desetino vezavne afinitete matične molekule do receptorjev MT1 in MT2.
The most abundant peaks in plasma after a single-dose of 100 mg 14C-opicapone are metabolites BIA 9-1103 (sulphate) and BIA 9-1104 (methylated), 67.1 and 20.5% of radioactive AUC
Z največjo koncentracijo v plazmi po enkratnem odmerku 100 mg 14C-opikapona sta zastopana presnovka BIA 9-1103 (sulfat) in BIA 9-1104 (metiliran), ki predstavljata 67,1 oz.
The most abundant plasma metabolite was M1, which represented 21% of drug-related radioactivity (AUC) in circulation following single dose; it’s formed via oxidative metabolism predominantly by CYP2C8.
Največ je bilo v plazmi presnovka M1, ki je predstavljal 21 % z zdravilom povezane radioaktivnosti (AUC) v obtoku (AUC) po enkratnem odmerku; nastane z oksidativno presnovo, pretežno s CYP2C8.
The most appropriate dose depends on the severity of the anaemia and how long the dog has been anaemic, as well as the desired duration of the medicine’s effect.
Najprimernejši odmerek je odvisen od resnosti anemije in trajanja anemičnosti psa, kot tudi želenega trajanja učinkovanja zdravila.
The most appropriate MedDRA term is used to describe a certain reaction and its synonyms and related conditions.
Za opis reakcij, sinonimov in povezanih bolezni so uporabljeni najustreznejši izrazi po MedDRA.
The most appropriate strategies to monitor the off label use within national territories
o najustreznejših strategijah za nadzor nenamenske uporabe zdravila znotraj nacionalnega območja,
The most clinically serious adverse event reported following multiple oral doses of  200 mg was hypotension which resolved following oral or intravenous fluid administration.
Klinično najresnejši neželeni učinek, o katerem so poročali po uporabi več peroralnih odmerkov  200 mg, je bila hipotenzija, ki je po uporabi peroralnega ali intravenskega vnosa tekočin izzvenela.
The most common (≥ 20%) adverse reactions observed following treatment with axitinib were diarrhoea, hypertension, fatigue, decreased appetite, nausea, weight decreased, dysphonia, palmar- plantar erythrodysaesthesia (hand-foot) syndrome, haemorrhage, hypothyroidism, vomiting, proteinuria, cough, and constipation.
Najpogostejši (≥ 20 %) neželeni učinki, ki so jih opažali po zdravljenju z aksitinibom, so bili driska, hipertenzija, utrujenost, zmanjšanje teka, navzea, zmanjšana telesna masa, hripavost, sindrom palmarno-plantarne eritrodisestezije (sindrom dlani-podplati), krvavitev, hipotiroidizem, bruhanje, proteinurija, kašelj in zaprtost.
The most common ADR leading to discontinuation was rash (2.2% in the INTELENCE arm versus 0% in the placebo arm).
Najpogostejši neželeni učinek, ki je vodil do ukinitve zdravila, je bil izpuščaj (2,2% v kraku študije z zdravilom INTELENCE v primerjavi z 0% v kraku študije s placebom).
The most common ADRs (≥ 50%) seen with Perjeta in combination with trastuzumab and docetaxel were diarrhoea, alopecia and neutropenia.
Najpogosteje (≥ 50 %) opaženi neželeni učinki zdravila Perjeta v kombinaciji s trastuzumabom in docetakselom so bili driska, alopecija in nevtropenija.
The most common adverse drug reactions (ADR) (> 30%) reported with vemurafenib include arthralgia, fatigue, rash, photosensitivity reaction, nausea, alopecia and pruritus.
Med najpogostejšimi neželenimi učinki (> 30 %), o katerih so poročali v zvezi z vemurafenibom, so artralgija, utrujenost, kožni izpuščaj, fotosenzibilnostna reakcija, navzea, alopecija in srbenje.
The most common adverse drug reactions (ADR) (at a higher incidence than placebo) for Plegridy
Najpogostejši neželeni učinki (pojavili so se z večjo incidenco kot placebo) za zdravilo Plegridy
The most common adverse drug reactions (ADR) occurring in ≥ 30 % of patients, were muscle spasms (74.6 %), alopecia (65.9%), dysgeusia (58.7%), weight decreased (50.0%), fatigue (47.1%), nausea (34.8 %) and diarrhea (33.3%).
Najpogostejši neželeni učinki zdravila, ki so se pojavili pri ≥ 30 % bolnikov, so bili krči mišic (74,6 %), alopecija (65,9 %), dizgevzija (58,7 %), zmanjšanje telesne mase (50,0 %), utrujenost (47,1 %), navzea (34,8 %) in driska (33,3 %).
The most common adverse drug reactions (ADRs) (≥ 10%) were akathisia and somnolence, which were dose-related up to 111 mg daily.
Najpogostejša neželena učinka (≥ 10 %) sta bila akatizija in somnolenca, ki sta bila povezana z odmerki do 111 mg na dan.
The most common adverse drug reactions (≥ 35%) reported during treatment with Dacogen are pyrexia, anaemia and thrombocytopaenia.
Neželeni učinki zdravila, o katerih so v času zdravljenja z zdravilom Dacogen najpogosteje poročali (≥ 35%), so zvišana telesna temperatura, anemija in trombocitopenija.
The most common adverse drug reactions in patients receiving Lonsurf that resulted in treatment discontinuation, dose reduction, dose delay, or dose interruption were neutropenia, general deterioration of health, anaemia, febrile neutropenia, fatigue, diarrhoea and dyspnoea.
Najbolj pogosti neželeni učinki pri bolnikih, zdravljenih z zdravilom Lonsurf, ki so imeli za posledico prenehanje zdravljenja, zmanjšanje odmerka, zakasnitev odmerka zdravila ali prekinitev, so bili nevtropenija, splošno poslabšanje zdravja, anemija, febrilna nevtropenija, utrujenost, diareja in dispneja.
The most common adverse drug reactions were eye pain and eye pruritus occurring in 1% to 2.0% of patients.
Najpogostejša neželena učinka sta bila očesna bolečina in očesni pruritus, ki sta se pojavila pri 1% do 2,0% bolnikov.
The most common adverse drug reactions were eye pain and eye pruritus, occurring in 1% to of 2.0% of patients.
Najpogostejša neželena učinka sta bila očesna bolečina in očesni pruritus, ki sta se pojavila pri 1% do 2,0% bolnikov.
The most common adverse events in children and adolescents 6 to 17 years of age were: Nervous system disorders:
Najpogostejši neželeni učinki pri otrocih in mladostnikih, starih od 6 do 17 let, so bili: Bolezni živčnega sistema:
The most common adverse reaction associated with both IZBA and Travoprost 40 µg/mL eye drops, solution is hyperaemia.
Najpogostejši neželeni učinek, povezan z zdravilom IZBA in kapljicami za oko s travoprostom v odmerku 40 µg/ml, je hiperemija.
The most common adverse reaction leading to discontinuation of Zurampic was blood creatinine increased (0.8%).
Najpogostejši neželeni učinek, ki je povzročil prenehanje zdravljenja z zdravilom Zurampic, je bilo zvišanje kreatinina v krvi (0,8 %).
The most common adverse reaction observed with Rasilez HCT is diarrhoea.
Med neželenimi učinki, ki jih opažajo pri uporabi zdravila Rasilez HCT, je najbolj pogosta driska.
The most common adverse reaction reported at a greater incidence in patients treated with the aprepitant regimen than with standard therapy in patients receiving Moderately Emetogenic Chemotherapy (MEC) was fatigue (1.4 % versus 0.9 %).
Najpogostejši neželeni učinek, o katerem so pri zmerno emetogeni kemoterapiji (MEC - Moderately Emetogenic Chemotherapy) poročali pogosteje pri bolnikih, ki so se zdravili z aprepitantom, kot bolnikih s standardno obliko zdravljenja, je bila utrujenost (1,4 % proti 0,9 %).
The most common adverse reactions (> 5%) in controlled periods of the adult psoriasis, psoriatic arthritis and Crohn’s disease clinical studies with ustekinumab were nasopharyngitis and headache.
Najpogostejši neželeni učinki (> 5%) v nadzorovanih obdobjih kliničnih študij psoriaze in psoriatičnega artritisa z ustekinumabom pri odraslih so bili nazofaringitis, glavobol in okužbe zgornjih dihal.
The most common adverse reactions (all grades, ≥20% incidence) reported at least 2% greater incidence for the ZALTRAP/FOLFIRI regimen as compared to the placebo/FOLFIRI regimen in order of decreasing frequency were leucopenia, diarrhoea, neutropenia, proteinuria, increased aspartate aminotransferase (AST), stomatitis, fatigue, thrombocytopenia, increased alanine aminotransferase (ALT), hypertension, weight loss, decreased appetite, epistaxis, abdominal pain, dysphonia, increased serum creatinine, and headache (see Table 1).
Najpogostejši neželeni učinki (vseh stopenj, incidenca ≥ 20 %), katerih incidenca je bila s shemo ZALTRAP/FOLFIRI vsaj 2 % večja od incidence s shemo placebo/FOLFIRI, so bili (v padajočem zaporedju pogostnosti): levkopenija, driska, nevtropenija, proteinurija, zvišana aspartat aminotransferaza (AST), stomatitis, utrujenost, trombocitopenija, zvišana alanin aminotransferaza (ALT), hipertenzija, zmanjšanje telesne mase, zmanjšanje apetita, epistaksa, bolečine v trebuhu, disfonija, zvišan kreatinin v serumu in glavobol (glejte preglednico 1).
The most common adverse reactions (experienced by at least 10 % of the patients) of any grade in the RCC and STS trials included: diarrhoea, hair colour change, skin hypopigmentation, exfoliative rash, hypertension, nausea, headache, fatigue, anorexia, vomiting, dysgeusia, stomatitis, weight decreased, pain, elevated alanine aminotransferase and elevated aspartate aminotransferase.
Najpogostejši neželeni učinki (ki so se pojavili vsaj pri 10 % bolnikov) katerekoli stopnje v preskušanjih pri RCC in STS so bili: driska, sprememba barve las, hipopigmentacija kože, eksfoliativen izpuščaj, hipertenzija, navzea, glavobol, utrujenost, anoreksija, bruhanje, disgevzija, stomatitis, zmanjšanje telesne mase, bolečina, zvišanje vrednosti alanin-aminotransferaze in zvišanje vrednosti aspartat-aminotransferaze.
The most common adverse reactions (incidence ≥ 20%) of ONIVYDE+5FU/LV were: diarrhoea, nausea, vomiting, decreased appetite, neutropenia, fatigue, asthenia, anaemia, stomatitis and pyrexia.
Najpogostejši neželeni učinki (pojavnost ≥ 20 %) zdravila ONIVYDE+5-FU/LV so bili: driska, navzea, bruhanje, zmanjšan apetit, nevtropenija, utrujenost, astenija, anemija, stomatitis in pireksija.
The most common adverse reactions (incidence ≥10%) for patients treated with Tecfidera were flushing and gastrointestinal events (i.e. diarrhoea, nausea, abdominal pain, abdominal pain upper).
Najpogostejši neželeni učinki (incidenca ≥ 10 %) za bolnike, zdravljene z zdravilom Tecfidera, so bili vročinsko oblivanje in prebavni dogodki (tj. driska, navzea, trebušne bolečine, bolečine v zgornjem delu trebuha).
The most common adverse reactions (occurring in > 20% of subjects) were: anaemia, fatigue, diarrhoea, thrombocytopenia, nausea, pyrexia, dyspnoea, respiratory tract infection, cough and peripheral oedema.
Najpogostejši neželeni učinki (pojavili so se pri > 20 % preiskovancev) so bili: anemija, utrujenost, driska, trombocitopenija, navzea, zvišana telesna temperatura, dispneja, okužba dihal, kašelj in periferni edemi.
The most common adverse reactions (≥ 20 %) for trametinib and dabrafenib combination therapy include pyrexia, fatigue, nausea, headache, chills, diarrhoea, rash, arthralgia, hypertension, vomiting and cough.
Med najpogostejšimi neželenimi učinki (≥ 20 %) kombiniranega zdravljenja s trametinibom in dabrafenibom so zvišana telesna temperatura, utrujenost, navzea, glavobol, mrzlica, diareja, izpuščaj, artralgija, hipertenzija, bruhanje in kašelj.
The most common adverse reactions (≥ 3% in pooled Phase 3 trials) occurring in patients receiving Zerbaxa were nausea, headache, constipation, diarrhoea, and pyrexia and were generally mild or moderate in severity.
Najpogostejši neželeni učinki (≥ 3 % v združenih preskušanjih 3. faze) pri bolnikih, ki so prejemali zdravilo Zerbaxa, so bili navzea, glavobol, zaprtje, diareja in zvišana telesna temperatura ter so bili večinoma blagi ali zmerni.
The most common adverse reactions (≥20%) for trametinib include rash, diarrhoea, fatigue, oedema peripheral, nausea, and dermatitis acneiform.
Med najpogostejšimi neželenimi učinki (≥ 20 %) trametiniba so izpuščaj, driska, utrujenost, periferni edemi, navzea in akneiformni dermatitis.
The most common adverse reactions (≥25%) in patients with either ALK-positive or ROS1-positive NSCLC were vision disorder, nausea, diarrhoea, vomiting, oedema, constipation, elevated transaminases, fatigue, decreased appetite, dizziness, and neuropathy.
Najpogostejši neželeni učinki (≥ 25 %) pri bolnikih z ALK-pozitivnim ali ROS1- pozitivnim NSCLC so bili motnje vida, navzea, diareja, bruhanje, edem, zaprtje, povečane vrednosti transaminaz, utrujenost, pomanjkanje apetita, omotica in nevropatija.
The most common adverse reactions (20%) for dabrafenib and trametinib combination therapy include pyrexia, fatigue, nausea, headache, chills, diarrhoea, rash, arthralgia, hypertension, vomiting and cough.
Med najpogostejšimi neželenimi učinki (≥ 20 %) kombiniranega zdravljenja z dabrafenibom in trametinibom so zvišana telesna temperatura, utrujenost, navzea, glavobol, mrzlica, diareja, izpuščaj, artralgija, hipertenzija, bruhanje in kašelj.
The most common adverse reactions are asthenia/fatigue, hot flush, headache, and hypertension.
Najpogostejši neželeni učinki so astenija/utrujenost, vročinski oblivi, glavobol in hipertenzija.
The most common adverse reactions are pharmacologically predictable adverse reactions of β2 adrenoceptor agonist therapy, such as tremor and palpitations.
Najpogostejši neželeni učinki, povezani z zdravilom, so farmakološko pričakovani neželeni učinki zdravljenja z agonisti adrenergičnih receptorjev β2, kot so tremor in palpitacije.
The most common adverse reactions are vomiting, nausea and constipation.
Najpogostejši neželeni učinki, so bruhanje, navzea in zaprtost.
The most common adverse reactions experienced by patients aged 6 years and older who received ivacaftor in the pooled 48-week placebo-controlled Phase 3 studies that occurred with an incidence of at least 3% and up to 9% higher than in the placebo arm were headache (23.9%), oropharyngeal pain (22.0%), upper respiratory tract infection (22.0%), nasal congestion (20.2%), abdominal pain (15.6%), nasopharyngitis (14.7%), diarrhoea (12.8%), dizziness (9.2%), rash (12.8%) and bacteria in sputum (12.8%).
Najpogostejši neželeni učinki pri bolnikih, starih najmanj 6 let, ki so prejemali ivakaftor v združenih 48-tedenskih, s placebom kontroliranih študijah faze 3, ki so se pojavili z incidenco vsaj 3 % in do 9 % večjo kot v skupini s placebom, so bili glavobol (23,9 %), bolečina v ustih in žrelu (22,0 %), okužbe zgornjih dihal (22,0 %), kongestija nosu (20,2 %), bolečine v trebuhu (15,6 %), nazofaringitis (14,7 %), driska (12,8 %), omotica (9,2 %), izpuščaj (12,8 %) in bakterije v sputumu (12,8 %).
The most common adverse reactions for Dynastat is nausea.
Najbolj pogost neželeni učinek zdravila Dynastat je navzea.
The most common adverse reactions in paediatric ITP patients 1 year and older (≥ 3% and greater than placebo) were upper respiratory tract infection, nasopharyngitis, cough, diarrhoea, pyrexia, rhinitis, abdominal pain, oropharyngeal pain, toothache, rash, increased AST and rhinorrhoea.
Najpogostejši neželeni učinki med pediatričnimi bolniki z ITP, ki so bili stari 1 leto ali več (neželeni učinki s pogostnostjo najmanj 3 % in hkrati večjo od pogostnosti pri bolnikih s placebom) so bili okužba zgornjih dihal, nazofaringitis, kašelj, driska, zvišana telesna temperatura, vnetje nosne sluznice, bolečine v trebuhu, orofaringealne bolečine, zobobol, izpuščaj, zvišana vrednost aspartat-aminotransferaze (AST) in rinoreja.
The most common adverse reactions leading to discontinuation during the first 16 weeks of treatment were diarrhoea (1.7%), and nausea (1.5%).
Najpogostejša neželena učinka, ki sta privedla do prekinitve jemanja zdravila v prvih 16 tednih zdravljenja, sta bila driska (1,7 %) in navzea (1,5 %).
The most common adverse reactions observed in clinical studies conducted with the Pandemic influenza vaccine H5N1 MedImmune in healthy adults was headache (25.4%) and upper respiratory infection (10.2%).
Najpogostejša neželena učinka v kliničnih študijah z Cepivom proti pandemski gripi H5N1 MedImmune pri zdravih odraslih sta bila glavobol (25,4 %) in okužba zgornjih dihal (10,2 %).
The most common adverse reactions occurring in at least 10% of patients included: headache, anaemia, decreased appetite, insomnia, cough, nausea, diarrhoea, alopecia, pruritus, myalgia, pyrexia, fatigue, influenza- like illness, asthenia, chills and peripheral oedema.
Med najbolj pogostimi neželenimi učinki, ki so se pojavili pri najmanj 10 % bolnikov, so bili: glavobol, anemija, zmanjšan apetit, nespečnost, kašelj, navzea, driska, alopecija, srbenje, mialgija, zvišana telesna temperatura, utrujenost, gripi podobno obolenje, astenija, mrazenje in periferni edemi.
The most common adverse reactions occurring in at least 10% of patients included: headache, anaemia, decreased appetite, insomnia, cough, nausea, diarrhoea, alopecia, pruritus, myalgia, pyrexia, fatigue, influenza-like illness, asthenia, chills and peripheral oedema.
Med najbolj pogostimi neželenimi učinki, ki so se pojavili pri najmanj 10 % bolnikov, so bili: glavobol, anemija, zmanjšan apetit, nespečnost, kašelj, navzea, driska, alopecija, srbenje, mialgija, zvišana telesna temperatura, utrujenost, gripi podobno obolenje, astenija, mrazenje in periferni edemi.
The most common adverse reactions occurring in at least 10% of patients included: headache, dizziness, insomnia, cough, dyspnoea, oropharyngeal pain, rhinorrhoea, nausea, diarrhoea, abdominal pain, transaminases increased, ecchymosis, arthralgia, muscle spasms, pain in extremity, fatigue, febrile neutropenia, and pyrexia.
Med najbolj pogostimi neželeni učinki, ki so se pojavili pri najmanj 10 % bolnikov, so bili: glavobol, omotica, nespečnost, kašelj, dispneja, orofaringealna bolečina, rinoreja, navzea, driska, bolečine v trebuhu, zvišane vrednosti aminotransferaz, ekhimoze, artralgija, mišični krči, bolečine v okončinah, utrujenost, febrilna nevtropenija in zvišana telesna temperatura.
The most common adverse reactions occurring in ≥ 1 % of patients treated with dalbavancin were nausea (2.4 %), diarrhoea (1.9 %), and headache (1.3 %) and were generally of mild or moderate severity.
Najbolj pogosti neželeni učinki, ki so se pojavili pri ≥ 1 % pacientov, ki so se zdravili z dalbavancinom, so bili navzea (2,4 %), driska (1,9 %) in glavobol (1,3 %) in so bili v glavnem blagi do zmerni.
The most common adverse reactions occurring in ≥ 3% of patients treated with Zinforo were nausea, headache, and rash.
Najpogostejši neželeni učinki, ki so se pojavili pri ≥ 3 % bolnikov, zdravljenih z zdravilom Zinforo, so bili navzea, glavobol in izpuščaj.
The most common adverse reactions of any grade (experienced by patients in RCC, GIST, and pNET registrational trials) included decreased appetite, taste disturbance, hypertension, fatigue, gastrointestinal disorders (i.e. diarrhoea, nausea, stomatitis, dyspepsia and vomiting), skin discolouration, and palmar-plantar erythrodysaesthesia syndrome.
Najpogostejši neželeni učinki katerekoli stopnje (ki so se pojavili pri bolnikih v RCC, GIST in pNET registracijskih preskušanjih) so zmanjšan tek, motnje okušanja, hipertenzija, utrujenost, prebavne motnje (npr. diareja, navzea, stomatitis, dispepsija in bruhanje), obarvanje kože in sindrom palmarno-plantarne eritrodisestezije.
The most common adverse reactions reported during clinical development in a total of 1,651 patients/subjects were: dyspnoea (29%), headache (27%), flushing (23%), chest pain (19%), electrocardiogram ST segment changes (18%), gastrointestinal discomfort (15%) and dizziness (11%).
Najpogostejši neželeni učinki, o katerih so poročali med kliničnim razvojem pri skupaj 1.651 bolnikih/prostovoljcih, so bili: dispneja (29%), glavobol (27%), vročinski vali (23%), bolečina v prsih (19%), spremembe segmentov ST v elektrokardiogramu (18%), prebavno nelagodje (15%) in omotico (11%).
The most common adverse reactions reported for patients treated with Betmiga 50 mg during the three 12-week phase 3 double blind, placebo controlled studies are tachycardia and urinary tract infections.
Najpogostejša neţelena učinka poročana med uporabo 50 mg zdravila Betmiga v treh 12-tedenskih, dvojno slepih, s placebom kontroliranih študijah 3. faze sta bila tahikardija in okuţbe sečil.
The most common adverse reactions reported in conjunction with overdose in these cases included bradycardia, hypotension, oversedation, somnolence and cardiac arrest.
Med najpogostejše neželene učinke, ki so jih poročali v povezavi s prevelikim odmerjanjem v teh primerih, so sodili bradikardija, hipotenzija, čezmerna sedacija, somnolenca in srčni zastoj.
The most common adverse reactions reported in long-term clinical trials were dizziness (42%), nausea (30%), nystagmus (23%), confusional state (25%), gait abnormal (16%), memory impairment (13%), vision blurred (14%), headache (12%), asthenia (13%), vomiting (11%), and somnolence (10%).
Najpogostejši neželeni učinki, o katerih so poročali pri dolgoročnih kliničnih študijah, so bili omotičnost (42 %), slabost (30 %), nistagmus (23 %), zmedenost (25 %), nenormalna drža (16 %), motnje spomina (13 %), zamegljen vid (14 %), glavobol 12 %), astenija (13 %), bruhanje (11 %) in zaspanost (10 %).
The most common adverse reactions reported were malaise and fatigue, respiratory tract infections, throat and tonsil discomfort, headache, abdominal discomfort and pain, nausea, vomiting and diarrhoea.
Najpogosteje so poročali o naslednjih neželenih učinkih: slabem počutju in utrujenosti, okužbah dihal, neugodju v predelu grla in tonzil, glavobolu, neugodju in bolečinah v trebuhu, navzeji, bruhanju in diareji.
The most common adverse reactions resulting in discontinuation from the rufinamide treatment group were rash and vomiting.
Najpogostejša neželena učinka, ki sta povzročila izključitev iz skupine zdravljenja z rufinamidom,sta bila izpuščaj in bruhanje.
The most common adverse reactions seen are peripheral oedema, hypokalaemia, hypertension and urinary tract infection.
Najpogostejši neželeni učinki zdravila so periferni edemi, hipokaliemija, hipertenzija in okužbe sečil.
The most common adverse reactions were eye pain (19.2%), eye irritation (17.8%), lacrimation (6. 4%), ocular hyperaemia (5.5%) and eyelid erythema (1.7%) which were usually transitory and occurred during instillation.
Najpogostejši neželeni učinki so bili bolečina v očesu (19,2 %), draženje očesa (17,8 %), solzenje (6,4 %), očesna hiperemija (5,5 %) in eritem veke (1,7 %), ki so bili običajno prehodni in so se pojavili med vkapanjem.
The most common adverse reactions were headache, nasopharyngitis, back pain, and arthralgia , which were common, by MedDRA definition, in both the Circadin and placebo treated groups.
Najpogostejši neželeni učinki so bili glavobol, nazofaringitis, bolečine v hrbtu in artralgija, ki so bili, po opredelitvi MedDRA, pogosti v obeh skupinah, v skupini, ki je prejemala zdravilo Circadin in v skupini, ki je prejemala placebo.
The most common adverse reactions were nausea and dizziness.
Najpogostejša sta bila navzea in omotica.
The most common adverse reactions were peripheral oedema and dizziness, see also section 4.8. The adverse reactions reported were in agreement with those anticipated from the safety profiles of the components telmisartan and amlodipine.
Najpogostejša neželena učinka sta bila periferni edem in omotica; glejte tudi poglavje 4.8. Neželeni učinki, o katerih so poročali, so se ujemali z učinki, ki veljajo za pričakovane na podlagi varnostnih profilov učinkovin zdravila, telmisartana in amlodipina.